Vincent T. DeVita

Vincent T. DeVita

Vincent T. DeVita, Jr., MD is an internationally recognized pioneer physician in the field of oncology.

DeVita earned his Bachelor of Science degree from the College of William and Mary in 1957. He was awarded his MD degree with distinction from the George Washington University School of Medicine in 1961.

DeVita spent the early part of his career at the National Cancer Institute (NCI). In 1980, the president of the United States appointed him as director of the NCI and the National Cancer Program, a position he held until 1988. While at the NCI, he was instrumental in developing combination chemotherapy programs that ultimately led to an effective regimen of curative chemotherapy for Hodgkin's disease and diffuse large cell lymphomas. Along with colleagues at the NCI, he developed the four-drug combination, known by the acronym MOPP, which increased the cure rate for patients with advanced Hodgkin's disease from nearly zero to over 70%.

In addition, in collaboration with Dr. George Canellos, DeVita developed the combination chemotherapy CMF, which still remains a useful therapy for breast cancer.

DeVita was the Director of Yale Cancer Center from 1993 to 2003. He is currently the chair of the Yale Cancer Center advisory board and is professor of internal medicine and of epidemiology and public health at Yale's medical school.

DeVita currently serves on the editorial boards of numerous scientific journals and is the author or co-author of more than 450 scientific articles. He is one of the three editors of Cancer: Principles and Practice of Oncology and serves as the editor-in-chief of The Cancer Journal.